Nasdaq · CIK 0001500198
NMTC NEUROONE MEDICAL TECHNOLOGIES Corp
Insider trading from SEC Form 4. Last filing 35 d ago. Close $1.12 on Oct 9, 2026, +14% from the 52-week low and -82% from the high.
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has 49 SEC Form 4 filings on file from 11 insiders, the latest filed on Sep 8, 2026. In the last 90 days insiders made 1 open-market buy worth $67k and 0 open-market sells worth $0, net +$67k.
11 open-market trades have been scored at NMTC. The newest: David J. Wambeke (Chief Business Officer) bought $67k of stock on Aug 27, 2026, filed Sep 8, 2026, scored 26 (weak). The largest of the 11 shown: David J. Wambeke (Chief Business Officer) bought $670k on Mar 1, 2026, scored 51 (moderate). 2 insiders bought within 14 days of each other around Apr 4, 2025.
NMTC closed at $1.12 on Oct 9, 2026, 14% above its 52-week low and 82% below its 52-week high.
2 Form 144 notices of planned sales are on file, the latest filed Aug 20, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NEUROONE MEDICAL TECHNOLOGIES Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 26Weak | David J. Wambeke Chief Business Officer buy | $67k 33,333 shares | +20% | - | |
| 15Weak | Mark Christianson Business Development Director sell | $11k 15,363 shares | -7% | +73% from low-30% from high | |
| 15Weak | Mark Christianson Business Development Director sell | $734 917 shares | -0% | +83% from low-27% from high | |
| 15Weak | Mark Christianson Business Development Director sell | $11k 13,720 shares | -6% | +84% from low-27% from high | |
| 51Moderate | David J. Wambeke Chief Business Officer buy | $670k 1,000,000 shares | - | +56% from low-40% from high | |
| 20Weak | Mark Christianson Business Development Director sell | $22k 30,000 shares | -11% | +84% from low-35% from high | |
| 15Weak | Mark Christianson Business Development Director sell | $5,804 10,000 shares | -4% | +40% from low-51% from high | |
| 15Weak | Mark Christianson Business Development Director sell | $5,596 8,981 shares | -3% | +40% from low-51% from high | |
| 15Weak | Mark Christianson Business Development Director sell | $7,306 11,019 shares | -4% | +54% from low-46% from high | |
| 68Notable | Ronald W. McClurg Chief Financial Officer buy | $100k 200,000 shares | +82% | 0% from low-61% from high | |
| 61Notable | David A Rosa CEO and President buy | $50k 100,000 shares | +9% | 0% from low-61% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 20, 2025 | Christianson Mark Officer | 30,000 0.06% of outstanding | $24k | Aug 20, 2025 | none |
| Mar 14, 2025 | Christianson Mark Co-Founder, VP of Business Communication,Affiliate | 30,000 0.10% of outstanding | $31k | Mar 14, 2025 | none |
Transactions
The newest 50 of 61 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | David J. Wambeke Chief Business Officer | POpen-market purchase Common Stock | +33,333 | $2.01 | $67k | 199,999 | 35 d ago |
| Aug 28, 2026 | David J. Wambeke Chief Business Officer | AGrant or award Option to Purchase Common Stockderivative | +35,000 | $0.00 | $0 | 35,000 | 35 d ago |
| Apr 3, 2026 | Edward Andrle director | AGrant or award Common Stock | +41,929 | $0.00 | $0 | 133,932 | Apr 7, 2026 |
| Apr 3, 2026 | Paul Buckman director | AGrant or award Common Stock | +41,929 | $0.00 | $0 | 178,733 | Apr 7, 2026 |
| Apr 3, 2026 | Edward Andrle director | AGrant or award Option to Purchase Common Stockderivative | +26,036 | $0.00 | $0 | 26,036 | Apr 7, 2026 |
| Apr 3, 2026 | Paul Buckman director | AGrant or award Option to Purchase Common Stockderivative | +26,036 | $0.00 | $0 | 26,036 | Apr 7, 2026 |
| Mar 30, 2026 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -15,363 | $0.74 | $11k | 198,920 | Apr 1, 2026 |
| Mar 31, 2026 | Mark Christianson Business Development Director | FTax withholding Common Stock | -253 | $0.78 | $197 | 198,667 | Apr 1, 2026 |
| Mar 12, 2026 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -817 | $0.80 | $654 | 214,383 | Mar 16, 2026 |
| Mar 13, 2026 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -100 | $0.80 | $80 | 214,283 | Mar 16, 2026 |
| Mar 10, 2026 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -11,611 | $0.80 | $9,289 | 217,309 | Mar 12, 2026 |
| Mar 11, 2026 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -2,109 | $0.80 | $1,687 | 215,200 | Mar 12, 2026 |
| Mar 1, 2026 | David J. Wambeke Chief Business Officer | POpen-market purchase Common Stock | +1,000,000 | $0.67 | $670k | 1,000,000 | Mar 3, 2026 |
| Mar 1, 2026 | David J. Wambeke Chief Business Officer | AGrant or award Option to Purchase Common Stockderivative | +500,000 | $0.00 | $0 | 500,000 | Mar 3, 2026 |
| Feb 18, 2026 | Steve Mertens Chief Technology Officer | FTax withholding Common Stock | -7,376 | $0.68 | $5,016 | 153,047 | Feb 20, 2026 |
| Feb 18, 2026 | David A Rosa CEO and President | FTax withholding Common Stock | -71,325 | $0.68 | $49k | 1,082,590 | Feb 20, 2026 |
| Feb 18, 2026 | Mark Christianson Business Development Director | FTax withholding Common Stock | -1,812 | $0.68 | $1,232 | 228,920 | Feb 20, 2026 |
| Dec 31, 2025 | Mark Christianson Business Development Director | FTax withholding Common Stock | -253 | $0.76 | $192 | 230,732 | Jan 5, 2026 |
| Dec 31, 2025 | Steve Mertens Chief Technology Officer | FTax withholding Common Stock | -906 | $0.76 | $687 | 160,423 | Jan 5, 2026 |
| Dec 31, 2025 | David A Rosa CEO and President | FTax withholding Common Stock | +2,458 | $0.76 | $1,863 | 1,153,915 | Jan 5, 2026 |
| Dec 18, 2025 | Jason Richard Mills director | AGrant or award Common Stock | +7,758 | $0.00 | $0 | 7,758 | Jan 2, 2026 |
| Dec 18, 2025 | Jason Richard Mills director | AGrant or award Option to purchase common stockderivative | +4,806 | $0.00 | $0 | 4,806 | Jan 2, 2026 |
| Sep 30, 2025 | Mark Christianson Business Development Director | FTax withholding Common Stock | -253 | $0.89 | $225 | 230,985 | Oct 1, 2025 |
| Sep 30, 2025 | Steve Mertens Chief Technology Officer | FTax withholding Common Stock | -906 | $0.89 | $805 | 161,329 | Oct 1, 2025 |
| Sep 30, 2025 | David A Rosa CEO and President | FTax withholding Common Stock | -2,458 | $0.89 | $2,184 | 1,156,373 | Oct 1, 2025 |
| Sep 5, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -30,000 | $0.74 | $22k | 231,238 | Sep 9, 2025 |
| Jun 30, 2025 | Mark Christianson Business Development Director | FTax withholding Common Stock | -253 | $0.68 | $172 | 261,238 | Jul 2, 2025 |
| Jun 30, 2025 | Steve Mertens Chief Technology Officer | FTax withholding Common Stock | -906 | $0.68 | $614 | 162,235 | Jul 2, 2025 |
| Jun 30, 2025 | David A Rosa CEO and President | FTax withholding Common Stock | -2,458 | $0.68 | $1,667 | 1,158,831 | Jul 2, 2025 |
| Jun 23, 2025 | Jeffrey S Mathiesen director | AGrant or award Option to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Jun 25, 2025 |
| Jun 23, 2025 | Edward Andrle director | AGrant or award Option to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Jun 25, 2025 |
| Jun 23, 2025 | Paul Buckman director | AGrant or award Option to Purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Jun 25, 2025 |
| Jun 4, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -10,000 | $0.58 | $5,804 | 261,491 | Jun 5, 2025 |
| Jun 1, 2025 | Emily J. Johns General Counsel | AGrant or award Option to Purchase Common Stockderivative | +500,000 | $0.00 | $0 | 500,000 | Jun 3, 2025 |
| May 21, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -14 | $0.65 | $9 | 280,458 | May 23, 2025 |
| May 22, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -8,967 | $0.62 | $5,586 | 271,491 | May 23, 2025 |
| May 19, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -8,006 | $0.67 | $5,330 | 283,485 | May 21, 2025 |
| May 20, 2025 | Mark Christianson Business Development Director | SOpen-market sale Common Stock | -3,013 | $0.66 | $1,976 | 280,472 | May 21, 2025 |
| Apr 17, 2025 | Mark Christianson Business Development Director | AGrant or award Option to Purchase Common Stockderivative | +200,000 | $0.00 | $0 | 200,000 | Apr 21, 2025 |
| Apr 17, 2025 | Ronald W. McClurg Chief Financial Officer | AGrant or award Option to Purchase Common Stockderivative | +250,000 | $0.00 | $0 | 250,000 | Apr 21, 2025 |
| Apr 17, 2025 | Steve Mertens Chief Technology Officer | AGrant or award Option to Purchase Common Stockderivative | +200,000 | $0.00 | $0 | 200,000 | Apr 21, 2025 |
| Apr 17, 2025 | David A Rosa CEO and President | AGrant or award Option to Purchase Common Stockderivative | +750,000 | $0.00 | $0 | 750,000 | Apr 21, 2025 |
| Apr 17, 2025 | Christopher Volker Chief Operating Officer | AGrant or award Option to Purchase Common Stockderivative | +575,000 | $0.00 | $0 | 575,000 | Apr 21, 2025 |
| Apr 4, 2025 | Ronald W. McClurg Chief Financial Officer | POpen-market purchase Common Stock | +200,000 | $0.50 | $100k | 444,117 | Apr 7, 2025 |
| Apr 4, 2025 | David A Rosa CEO and President | POpen-market purchase Common Stock | +100,000 | $0.50 | $50k | 1,161,289 | Apr 7, 2025 |
| Mar 31, 2025 | Mark Christianson Business Development Director | FTax withholding Common Stock | -253 | $0.85 | $215 | 291,491 | Apr 2, 2025 |
| Mar 31, 2025 | Steve Mertens Chief Technology Officer | FTax withholding Common Stock | -906 | $0.85 | $770 | 163,141 | Apr 2, 2025 |
| Mar 31, 2025 | David A Rosa CEO and President | FTax withholding Common Stock | -2,458 | $0.85 | $2,090 | 1,061,289 | Apr 2, 2025 |
| Feb 18, 2025 | Mark Christianson Business Development Director | FTax withholding Common Stock | -1,812 | $1.16 | $2,102 | 291,744 | Feb 20, 2025 |
| Feb 14, 2025 | Edward Andrle director | AGrant or award Common Stock | +27,778 | $0.00 | $0 | 92,003 | Feb 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Edward Andrledirector
- Paul Buckmandirector
- Mark ChristiansonBusiness Development Director
- Emily J. JohnsGeneral Counsel
- Jeffrey S Mathiesencfo, officer, director
- Ronald W. McClurgChief Financial Officer
- Steve MertensChief Technology Officer
- Jason Richard Millsdirector
- David A RosaCEO and President
- Christopher VolkerChief Operating Officer
- David J. WambekeChief Business Officer
Questions about NMTC
Answered from the filings on this page, as of the latest one.
Are insiders buying NMTC?
As of Sep 8, 2026, SEC Form 4 filings show 1 open-market buy worth $67k by 1 insider and 0 open-market sells worth $0 by 0 insiders at NEUROONE MEDICAL TECHNOLOGIES Corp in the last 90 days, net +$67k. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade NMTC on the open market?
David J. Wambeke (Chief Business Officer) bought $67k of NMTC on Aug 27, 2026 and filed the Form 4 on Sep 8, 2026. InsiderTell scored 26 (weak).
How many insiders file Form 4 at NEUROONE MEDICAL TECHNOLOGIES Corp?
11 people have filed a Form 4 at NEUROONE MEDICAL TECHNOLOGIES Corp, among them Edward Andrle (director), Paul Buckman (director), Mark Christianson (Business Development Director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.